Physician profile
David A Chappell
NPI 1598732463
$10,922.24
in general payments reported to CMS, 2019-2025
44 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $1,231 · 2021: $2,400 · 2022: $1,699 · 2023: $1,357 · 2024: $1,791 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,238 · Education: $94.51 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.95 |
| Education | $94.51 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,815.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,132.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,100.48 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Radius Health, INC. | $1,030.79 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $806.11 | 2019-2025 | Jardiance |
| Amgen INC. | $664.99 | 2019-2025 | Tepezza, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $561.80 | 2019-2022 | |
| Welch Allyn | $436.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $349.13 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $310.09 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $274.03 | 2021-2023 | Afrezza |
| Amarin Pharma, INC. | $239.20 | 2020-2021 | |
| Baxter Healthcare | $218.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $188.56 | 2019-2022 | |
| Pfizer INC. | $142.49 | 2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chappell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.